Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use of Angiotensin-converting Enzyme Inhibitors in Patients Receiving Lung Stereotactic Body Radiation Therapy
- 1 June 2018
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 41 (6) , 576-580
Abstract
Angiotensin-converting enzyme inhibitors (ACEi) have demonstrated decreased rates of radiation-induced lung injury in animal models and clinical reports have demonstrated decreased pneumonitis in the setting of conventionally fractionated radiation to the lung. We tested the role of ACEi in diminishing rates of symptomatic (grade ≥2) pneumonitis in the setting of lung stereotactic body radiation therapy (SBRT). We analyzed patients treated with thoracic SBRT to 48 to 60 Gy in 4 to 5 fractions from 2006 to 2014. We reviewed pretreatment and posttreatment medication profiles to document use of ACEi, angiotensin receptor blockers, bronchodilators, aspirin, PDE-5 inhibitors, nitrates, and endothelin receptor antagonists. Pneumonitis was graded posttreatment based on Common Terminology Criteria for Adverse Events Version 4.0. Univariate and multivariate analysis was performed and time to development of pneumonitis was evaluated by the Kaplan-Meier method. A total of 189 patients were evaluated with a median follow-up of 24.8 months. The overall 1-year rate of symptomatic pneumonitis was 13.2%. The 1-year rate of symptomatic pneumonitis was 4.2% for ACEi users versus 16.3% in nonusers (P=0.03). On univariate analysis, the odds of developing grade 2 or greater pneumonitis were significantly lower for patients on ACEi (P=0.03). On multivariate analysis, after controlling for clinicopathologic characteristics and dosimetric endpoints, there was a significant association between ACEi use and decreased risk of clinical pneumonitis (P=0.04). Angiotensin receptor blockers or other bronchoactive medications did not show significant associations with development of pneumonitis. Incidental concurrent use of ACEi demonstrated efficacy in diminishing rates of symptomatic pneumonitis in the setting of lung SBRT.Keywords
This publication has 23 references indexed in Scilit:
- Results of the Two Incidence Screenings in the National Lung Screening TrialNew England Journal of Medicine, 2013
- Decreased Risk of Radiation Pneumonitis With Incidental Concurrent Use of Angiotensin-Converting Enzyme Inhibitors and Thoracic Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- An Improved Model for Predicting Radiation Pneumonitis Incorporating Clinical and Dosimetric VariablesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Renin-Angiotensin System Suppression Mitigates Experimental Radiation PneumonitisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- An Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation OncologySeminars in Radiation Oncology, 2008
- A Nomogram to Predict Radiation Pneumonitis, Derived From a Combined Analysis of RTOG 9311 and Institutional DataInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Radiation effects on the respiratory systemBritish Journal of Radiology, 2005
- Radiation-induced lung injurySeminars in Radiation Oncology, 2003
- Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blockerInternational Journal of Radiation Biology, 2000
- Bias reduction of maximum likelihood estimatesBiometrika, 1993